Mainz, Germany
BioNTech SE, founded in 2008, is a Germany-based leader in Biopharma and Biotechnology industries. Upholding the vision to harness the immune system against cancer and infectious diseases, the company specializes in developing cutting-edge immunotherapies.
Their impressive global presence, reflected by a workforce of around 6,100, leverages a multitude of computational discovery and therapeutic platforms. Their oncology portfolio is particularly noteworthy, featuring mRNA-based therapies, chimeric antigen receptor (CAR) T cells, and innovative protein-based therapeutics.
BioNTech is also at the forefront of mRNA vaccine development, expanding beyond oncology to tackle a range of infectious diseases. Their in-house manufacturing capabilities further bolster their market position.
The company's recent financial milestone, a $145.00M post-IPO equity investment, was led by the Coalition for Epidemic Preparedness Innovations on May 29, 2024. This investment underscores confidence in BioNTech's innovative potential and long-term growth prospects.
